Kymera Therapeutics (KYMR) Jefferies Global Healthcare Conference 2026 summary

Company overview and strategy

• Celebrated 10 years, focusing on targeted protein degradation to address previously undrugged or poorly drugged targets in validated pathways.

• Leading programs include KT-621 (STAT6 degrader) for type 2 inflammation and IRF5 targeting for immunology.

• Two global Phase IIb studies underway, with productive collaborations in immunology and oncology.

• Rich preclinical pipeline with plans to share new programs as they enter IND-enabling stages.

Clinical development and trial execution

• BROADEN2 (atopic dermatitis) and BREADTH (eosinophilic asthma) are global Phase IIb, dose-ranging, placebo-controlled studies using the same three doses plus placebo.

• Enrollment for BROADEN2 began late last year, aiming for 200 patients, with completion expected by year-end and data by mid-next year.

• Dose selection based on achieving >90% target degradation, with plans to select a single optimal dose for Phase III if possible.

• Rigorous operational oversight to ensure high-quality patient selection, consistent investigator training, and close monitoring to minimize placebo effects.

Study design and patient population

• BROADEN2 allows prior IL-4/IL-13 drug exposure (non-failures), aiming to explore transition from injectables to oral therapy.

• Patient baseline severity (EASI ~25) aligns with industry norms, with sophisticated approaches to ensure high patient quality.

• Focus on enrolling moderate to severe atopic dermatitis patients and maintaining study integrity through strict oversight.